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Abstract
Rationale Cariprazine, a dopamine D3/D2 receptor par-
tial agonist antipsychotic, demonstrated efficacy and tol-
erability in 6-week, randomized, placebo-controlled
schizophrenia trials. Schizophrenia is a chronic disorder
that requires continuous treatment; therefore, the long-
term safety and tolerability profile of antipsychotic
agents is an important factor in guiding clinician
decisions.
Objective This single-arm, open-label extension study evalu-
ated the long-term safety and tolerability of cariprazine in
patients with schizophrenia.
Methods Patients enrolled in this study completed a 6-
week, randomized, placebo- and active-controlled study
and had responded (Clinical Global Impressions-Severity
[CGI-S] ≤3; ≥20 % reduction in Positive and Negative
Syndrome Scale [PANSS] total score) to treatment at the
end of the lead-in study. Patients (N = 93) received
flexibly dosed, open-label cariprazine (1.5–4.5 mg/day)
for up to 48 weeks.
Results Approximately 50 % (46/93) of patients completed
the 48 weeks of open-label treatment. The most common ad-
verse events (AEs) were akathisia (14 %), insomnia (14 %),
and weight increased (12 %). Serious AEs (SAEs) occurred in
13% of patients; 11 % discontinued due to AEs. Mean chang-
es in metabolic parameters were generally small and not clin-
ically relevant. Mean body weight increased by 1.9 kg from
the start of the lead-in study to the end of the extension study.
There were no discontinuations associated with change in
metabolic parameters or body weight. Long-term cariprazine
treatment was not associated with prolactin elevation or clin-
ically significant changes in cardiovascular parameters.
Conclusions In this 48-week, single-arm trial, open-label
cariprazine (1.5–4.5 mg/day) treatment was generally safe
and well tolerated with no new safety concerns associated
with long-term treatment.
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Introduction
Long-term treatment of schizophrenia remains a clinical chal-
lenge due to the high percentage of patients who experience
recurring relapses over the course of illness (Robinson et al.
1999). A major factor for increased risk of relapse is lack of
compliance or discontinuation of antipsychotic therapy
(Robinson et al. 1999), which may be due to poor tolerability
or loss of efficacy of the medication (Ascher-Svanum et al.
2010; Perkins 2002; Yamada et al. 2006).
While atypical antipsychotics generally result in fewer ex-
trapyramidal symptoms (EPS) than first-generation agents,
these compounds have the potential to induce adverse effects
such as weight gain, metabolic changes, cardiovascular ad-
verse events (AEs), hyperprolactinemia, and EPS (Leucht
et al. 1999; Weiden 2007). The incidence of these adverse
effects may differ significantly among currently available
agents; therefore, understanding the tolerability profiles of
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currently available and new antipsychotics is an important
component of effective clinical management of schizophrenia
and should help guide treatment decisions. Although antipsy-
chotic efficacy is thought to be principally mediated by D2
receptor occupancy (Nord and Farde 2011), currently avail-
able antipsychotics also have varying levels of affinity for
additional neuroreceptors. These differences in receptor affin-
ities may account for the variation among antipsychotics in
efficacy, tolerability, and side effect profiles (Leucht et al.
2013). Antipsychotics with new receptor profiles that are gen-
erally well tolerated and show sustained efficacy across a
broad range of symptoms are needed for improving long-
term patient outcomes.
Cariprazine is an atypical antipsychotic that is approved in
the USA for the treatment of schizophrenia and manic or
mixed episodes associated with bipolar I disorder. It has a
distinct pharmacological profile in that it shows potent dopa-
mine D3 and D2 receptor partial agonism and preferential
in vitro binding to D3 receptors (Kiss et al. 2010). In vivo,
cariprazine demonstrates high occupancy of both D3 and D2
receptors at antipsychotic effective doses in rats (Gyertyán
et al. 2011) and clinically active dose ranges in patients with
schizophrenia (Girgis et al. 2016). This pharmacological
profile differs from other atypical antipsychotics such as
aripiprazole, clozapine, olanzapine, and risperidone, which
have varying levels of in vitro affinity for D3 receptors but fail
to show D3 receptor occupancy at clinically relevant doses
(Caravaggio et al. 2014; Graff-Guerrero et al. 2009; Mizrahi
et al. 2011). The D3 receptor is thought to play a role in mood
and cognition (Gross and Drescher 2012), and cariprazine was
developed based on the hypothesis that a compound that ex-
hibits high in vivo binding affinity at both D3 and D2 receptors
may confer benefits in treating the negative and cognitive
symptoms associated with schizophrenia (Gyertyán et al.
2008; Joyce and Millan 2005; Kiss et al. 2008; Leriche et al.
2004; Zimnisky et al. 2013). Of note, cariprazine has demon-
strated efficacy in clinical studies as monotherapy for bipolar I
depression and as adjunctive therapy for major depressive
disorder (Durgam et al. 2016a; Durgam et al. 2016c).
Additionally, in a randomized, double-blind, active-
controlled trial, cariprazine was significantly more effective
than risperidone in treating predominant negative symptoms
of schizophrenia and improving associated psychosocial im-
pairment (Debelle et al. 2015).
Cariprazine also acts as an antagonist at serotonin 5-HT2B
receptors and as a partial agonist at 5-HT1A receptors, with
lower affinity for 5-HT2A, 5-HT2C, histamine H1, and adren-
ergic α1 receptors and negligible affinity at other receptors
(Kiss et al. 2010). This distinct receptor binding profile may
have beneficial implications for the cardiovascular (Leung
et al. 2012), metabolic (Nasrallah 2008), sedative (Miller
2004), and hyperprolactinemia (Kapur and Seeman 2001) side
effects that are associated with some antipsychotics.
The efficacy and safety of cariprazine (dose ranges 1.5–
9 mg/day) were evaluated in short-term, randomized,
placebo- and active-controlled phase IIb (Durgam et al.
2014) and phase III (Durgam et al. 2015; Kane et al. 2015)
studies in patients with acute exacerbation of schizophrenia,
as well as a double-blind, placebo-controlled relapse preven-
tion study (Durgam et al. 2016b). This single-arm, open-label
extension study was conducted to evaluate the long-term safe-
ty and tolerability of cariprazine 1.5 to 4.5 mg/day in patients
that had completed 6 weeks of double-blind treatment during
a phase IIb, placebo- and active-controlled lead-in study of
cariprazine in patients with acute exacerbation of schizophre-
nia (Durgam et al. 2014).
Methods
This was a multicenter, single-arm, open-label, flexible-dose,
53-week extension study (RGH-MD-17; NCT00839852) for
outpatients who had completed 6 weeks of double-blind treat-
ment with cariprazine (1.5, 3.0, or 4.5 mg/day), placebo, or
risperidone 4.0 mg/day in a phase IIb lead-in study in patients
with acute exacerbation of schizophrenia (RGH-MD-16;
NCT00694707) (Durgam et al. 2014). This extension study
was initiated 9 months after the initiation of the lead-in study;
it was conducted between March 2009 and August 2010 at 40
study centers located in the USA (9), India (10), Malaysia (2),
Russia (9), and Ukraine (10). It was designed in accordance
with IHC and FDA GCP Guidelines; all participants provided
written informed consent.
Study design
The 53-week extension study comprised a no-drug screening
period (3–7 days), 48 weeks of open-label treatment, and a 4-
week safety follow-up period. Cariprazine was initiated at
1.5 mg/day, with 1.5-mg dose increases possible on days 2
and 3 depending on response and tolerability (based on inves-
tigator judgment) to a maximum dose of 4.5 mg/day.
Decreases in dose by 1.5-mg/day decrements or a drug holi-
day of up to 3 days were allowed if there were tolerability
issues. Patients may have been hospitalized during screening
at the discretion of the investigator, and all patients were hos-
pitalized during the first week of open-label treatment. After
1 week of open-label treatment, patients could be discharged
and followed-up as outpatients or remain hospitalized for an
additional week at the discretion of the investigator; patients
could be rehospitalized at any time. Patients were evaluated
weekly for the first 6 weeks of open-label treatment and bi-
weekly for the duration of the study. Patients who completed
48 weeks of treatment or prematurely discontinued were eval-
uated for an additional 4 weeks during the safety follow-up
period.
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Inclusion/exclusion criteria
Inclusion and exclusion criteria for the lead-in study have
been previously described in detail (Durgam et al. 2014).
Briefly, patients were 18 to 60 years of age and met the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) criteria for
schizophrenia with a current exacerbation of schizophrenia.
Patients were required to have had the diagnosis for at least
1 year, with at least one previous psychotic episode, and have
a Positive and Negative Symptoms Scale (PANSS) (Kay et al.
1987) total score of 80 to 120, inclusive (indicating moderate
to severe symptoms), and a Clinical Global Impressions-
Severity (CGI-S) (Guy 1976b) score ≥4 (moderately ill or
worse).
Inclusion criteria for patients entering the extension study
were the same as for the lead-in study, except that patients
must have completed double-blind treatment in the lead-in
study as outpatients, with CGI-S score ≤3 (mildly ill or better)
and a ≥20 % reduction from lead-in study baseline in PANSS
total score at the end of the lead-in study. Patients were also
required to have normal physical examination, clinical labo-
ratory, vital sign, and electrocardiogram (ECG) results or ab-
normal results that were not considered clinically significant.
Designated caregivers were required to accompany outpa-
tients at each visit or, in the case that they could not attend a
visit, provide written documentation of patient’s study medi-
cation compliance.
Typical clinical trial exclusions were applied, including
clinically significant, uncontrolled AEs or EPS during the
lead-in study; pregnancy; significant risk for suicidal or vio-
lent behavior; various ophthalmology assessment criteria
(e.g., history or current findings of ocular disease, history of
intraocular surgery, laser treatment, or ocular trauma); and
injection of a depot antipsychotic or electroconvulsive therapy
since the lead-in study. Psychotropic medications were
prohibited for the duration of the open-label study with the
exception of SSRIs (citalopram, escitalopram, fluoxetine,
fluvoxamine, or sertraline) and divalproex (with approval
from the study physician). Zolpidem, zaleplon, eszopiclone,
or chloral hydrate were permitted for insomnia; diphenhydra-
mine, benztropine, or propranolol were permitted as EPS res-
cue medication; and lorazepam was permitted to control agi-
tation, irritability, and hostility.
Outcome assessments
Safety parameters included AEs, clinical laboratory parame-
ters, vital signs, ECGs, and ophthalmologic examinations
(e.g., Lens Opacities Classification System III). Suicidality
was evaluated by the Suicidality Tracking Scale (STS)
(Coric et al. 2009), an 8-item rating scale from 0 (“not at
all”) to 4 (“extremely”) used to evaluate suicidality based on
suicidal ideation and behavior. EPS was evaluated by the
Barnes Akathisia Scale (BARS) (Barnes 1989), Abnormal
Involuntary Movement Scale (AIMS) (Guy 1976a), and the
Simpson-Angus Scale (SAS) (Simpson and Angus 1970).
Efficacy was assessed by the PANSS and CGI-S scales; be-
cause the objective of the extension study was to evaluate the
long-term safety and tolerability of cariprazine and there was
no comparator group, efficacy assessments were not catego-
rized as primary, secondary, or additional outcomes.
Statistical analysis
All safety analyses were based on the safety population, which
comprised all patients who took at least one dose of open-label
cariprazine in this extension study; descriptive statistics were
performed for safety parameters. The baseline of the lead-in
study was used as the baseline for all safety parameters anal-
yses (except for STS and ophthalmologic examination, which
used the extension baseline since no lead-in baseline values
were available). In this long-term safety study, use of the lead-
in study baseline ensured that the reported safety outcomes
were based on total cariprazine exposure. Mean changes in
safety parameters were evaluated from baseline to end of
study, with end of study values defined as the last available
assessment during the open-label treatment period. AEs were
considered treatment-emergent adverse events (TEAEs) if the
AE started during open-label treatment and was not present
before the first dose of double-blind treatment during the lead-
in study or increased in intensity following the first dose of
open-label treatment. AEs were analyzed separately for the
safety follow-up period. Treatment-emergent parkinsonism
was defined as an SAS score ≤3 at baseline and >3
postbaseline; treatment-emergent akathisia was defined as a
BARS score ≤2 at baseline and >2 postbaseline.
All efficacy analyses were based on the intent-to-treat
(ITT) population, which included patients from the safety
population who had at least one efficacy assessment in this
extension study. Efficacy analyses were performed using both
the observed cases (OC) approach and the last observation
carried forward (LOCF) approach; no inferential statistical
analyses were performed for efficacy parameters.
Results
Patient disposition and demographics
Of the 464 patients who completed the lead-in study (RGH-
MD-16), 97 patients enrolled in the extension study, and 93
received at least one dose of cariprazine (safety population,
Fig. 1). Since the extension study was not initiated until
9 months after initiation of the lead-in study, a low number
of completers were available to participate in the extension
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study. Of the 93 patients who received open-label cariprazine,
over half (57.0 %) had received cariprazine in the lead-in
study; 26.9 and 16.1 % had received risperidone and placebo,
respectively. Per study protocol, patients were hospitalized for
the first week of open-label treatment; 11 were rehospitalized
due to clinical deterioration at a later point during the study.
Demographics and characteristics of the safety population at
baseline of the extension study are shown in Table 1. The
mean duration of schizophrenia in the lead-in study was
11.6 years. A total of 92 patients in the safety population
had at least 1 efficacy evaluation (ITT population), 46 patients
completed the study, and 67 patients entered the safety follow-
up period. Open-label discontinuations occurred in 47, 50, 54,
50, and 52% of patients who had been randomized to placebo,
cariprazine 1.5 mg/day, cariprazine 3.0 mg/day, cariprazine
4.5 mg/day, and risperidone 4.0 mg/day, respectively, in the
lead-in study. The most frequent reasons for discontinuation
during the open-label treatment period were withdrawal of
consent (17.2 %) and AEs (10.8 %).
Safety
Extent of exposure
The mean (SD) duration of cariprazine treatment was 221.7
(132.7) days; 46 patients (approximately 50 %) were exposed
to cariprazine for at least 1 year. Patient-years of exposure
(total treatment duration for all patients in days/365.25) was
56.4. Cariprazine 4.5 mg/day was the final dose for 70 % of
the patients and was also the modal dose in 67.7 % of patients;
24.7 and 7.5 % of patients had modal daily doses of 3.0 and
1.5 mg/day, respectively.
Adverse events
Approximately 83 % of patients reported TEAEs, the most
common of which (reported in ≥5 % of patients) are shown
in Table 2. Approximately 80 % of patients reported an AE
that was newly emergent (NEAEs, AEs that emerged or in-
creased in severity after the first dose of open-label
cariprazine). Most (72.9 %) were mild in intensity and 61 %
were considered to be related or possibly related to cariprazine
treatment. Most frequently reported TEAEs occurred early in
treatment, and no unanticipated AEs emerged with continued
long-term cariprazine therapy (Table 3). The only TEAEs that
Table 1 Demographics and baseline characteristics (safety population)
Cariprazine, N = 93
Lead-in study treatment group, n (%)
Placebo 15 (16.1)
Cariprazine 1.5 mg/day 16 (17.2)
Cariprazine 3.0 mg/day 13 (14.0)
Cariprazine 4.5 mg/day 24 (25.8)
Risperidone 4.0 mg/day 25 (26.9)
Extension study demographics and baseline characteristics
Age, mean (SD), years 34.4 (10.1)





Weight, mean (SD), kg 72.2 (17.7)
Height, mean (SD), cm 169.1 (10.7)
Waist circumference, mean (SD), cm 84.9 (11.2)
BMI, mean (SD), kg/m2 25.0 (4.5)
Fig. 1 Patient populations and
disposition. Superscript a: Since
the extension study was initiated
9 months after initiation of the
lead-in study, most completers
from the lead-in study were not
available for enrollment in the
extension study. Superscript b:
Includes patients who completed
the study, as well as those who
prematurely discontinued from
the study but entered safety
follow-up
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were considered treatment-related and occurred in ≥3 patients
were joint stiffness, akathisia, and tremor.
A total of 17 serious AEs (SAEs) were reported in 12
(12.9 %) patients during the open-label treatment period
(Table 2), 5 of which were considered related or possibly
related to treatment (exacerbation of schizophrenia [4 patients]
and agitation/intentional overdose [1 patient]). The only SAEs
that occurred in ≥2 patients were worsening of schizophrenia
(4 patients) and worsening of psychotic disorder (2 patients).
One death from suicide occurred after 327 days of treatment
with cariprazine 4.5 mg/day. The event was not considered
related to treatment; no trigger for the event was identified
and the patient had no history of suicidal ideation or behavior.
Ten patients (10.8 %) prematurely discontinued due to AEs
(four AEs [headache, pneumonia, sedation, insomnia] and six
SAEs [one completed suicide, one worsening of psychotic
condition, and four worsening of schizophrenia]).
Discontinuations due to AEs were distributed among patients
who came into the study from the placebo (n = 2), cariprazine
3.0 mg/day (n = 2), cariprazine 4.5 mg/day (n = 4), and ris-
peridone 4 mg/day (n = 2) treatment arms of the lead-in study.
During the 4-week safety follow-up, three patients reported
NEAEs, including two that were SAEs (worsening of schizo-
phrenia and lower-limb fracture).
Clinical laboratory values and metabolic parameters
Mean changes from lead-in baseline in clinical laboratory
values were generally small (Table 4). No clinically meaning-
ful changes from baseline to the end of treatment were ob-
served in liver function tests, and no patient met Hy’s Law
criteria (alanine aminotransferase [ALT] or aspartate amino-
transferase [AST] ≥3 × upper limit of normal [ULN] concur-
rent with total bilirubin ≥2 × ULN and alkaline phosphatase
<2 × ULN). Mean prolactin and creatine kinase levels de-
creased from baseline to end-of-treatment period.
Mean total and LDL cholesterol levels were decreased
from lead-in baseline to the end of the study, and small mean
increases in HDL cholesterol were observed (Table 4). The
incidence of clinically relevant lipid changes was low, with no
patients shifting from normal/borderline levels of total
(<240 mg/dL) or LDL (<160 mg/dL) cholesterol at baseline
to high levels (total, ≥240 mg/d; LDL, ≥160 mg/dL) at the end
of open-label treatment. Shifts from normal HDL cholesterol
levels (≥40 mg/dL) at baseline to low levels (<40 mg/dL) at
the end of open-label treatment occurred in 23.3 % of patients.
Mean increases in triglycerides and fasting glucose were small
and not clinically meaningful (Table 4). At the end of open-
label treatment, 13.9 % of patients had shifted from normal/
borderline to high levels of triglyceride (<200 to ≥200 mg/dL)
and 4.2 % of patients with normal fasting glucose levels
(<100 mg/dL) at baseline shifted to high levels (≥126 mg/
dL). Less than one third (29.2 %) of patients had an increase
in fasting glucose of ≥10 mg/dL. No metabolic change was
reported as an SAE or led to study discontinuation.
Cardiovascular and physical findings
Mean changes in ECG parameters from lead-in baseline to
endpoint were generally small and not clinically meaningful
(Table 5). During the open-label treatment period, no patient
had a QTcB or QTcF increase ≥60 ms or postbaseline value
>500ms. Changes in blood pressure and pulse rate were small
(Table 5). Orthostatic hypotension (≥20 mmHg reduction in
systolic blood pressure or ≥10 mmHg reduction in diastolic
blood pressure while changing from the supine to standing
position) was reported in approximately 25 % of patients dur-
ing the open-label treatment period, which is similar to the rate
reported by the placebo group in the lead-in study (23 %).
Only two patients with orthostatic hypotension also reported
TEAEs of dizziness; no other TEAEs suggestive of orthostatic
hypotension were reported.





Patients with any TEAE 77 (82.8)
Patients with NEAEs 74 (79.6)
Patients with SAEs 12 (12.9)
Deaths 1 (1.1)
Patients with AEs leading to premature discontinuation 10 (10.8)
Most frequent TEAEs (≥5 %)
Akathisia 13 (14.0)
Insomnia 13 (14.0)






Psychotic disorder 7 (7.5)
Schizophrenia 7 (7.5)
Tremor 7 (7.5)






AE adverse event, NEAE newly emergent AE (emerged or increased in
severity during extension study), SAE serious AE, TEAE treatment-emer-
gent AE (emerged or increased in severity during extension study or lead-
in study)
Psychopharmacology (2017) 234:199–209 203




Liver function, mean change (SD)a
ALT, U/L 91 0.9 (17.0)
AST, U/L 91 −0.7 (15.0)
Total bilirubin, mg/dL 91 0.05 (0.28)
Alkaline phosphatase, U/L 90 −4.6 (33.5)
`Prolactin, mean change (SD)a
Prolactin, ng/mL 80 −15.90 (26.73)
Creatine kinase, mean change (SD)a
Creatine kinase, U/L 91 −56.44 (398.98)
Lipids and glucose, mean change (SD)a
Total cholesterol, mg/dL 91 −5.02 (30.89)
Total LDL, mg/dL (calculated) 90 −4.63 (24.32)
Total HDL, mg/dL 91 1.93 (15.06)
Triglycerides, mg/dL 91 4.42 (113.27)
Fasting glucose, mg/dL 89 1.98 (24.14)
Clinically relevant shifts in lipids and glucose,b n (%)
Total cholesterol, normal/borderline (<240 mg/dL) to high (≥240 mg/dL) 82 0 (0.0)
Fasting LDL cholesterol, normal/ borderline (<160 mg/dL) to high (≥160 mg/dL) 81 0 (0.0)
HDL cholesterol, normal (≥40 mg/dL) to low (<40 mg/dL) 60 14 (23.3)
Fasting triglycerides, normal/borderline (<200 mg/dL) to high (≥200 mg/dL) 79 11 (13.9)
Fasting glucose, normal (<100 mg/dL) to high (≥126 mg/dL) 72 3 (4.2)
Fasting glucose, increase ≥10 mg/dL 89 26 (29.2)
N patients who had a lead-in baseline and ≥1 postbaseline measurement for the given parameter. ALT alanine
aminotransferase, AST aspartate aminotransferase, SD standard deviation
aMean changes are from lead-in baseline
bAt end of open-label treatment
Table 3 Most frequent adverse events (≥5 %) by time to first occurrences (safety population)
<6 weeks 6 to <12 weeks 12 to <24 weeks 24 to <36 weeks 36 to <48 weeks ≥48 weeks
Preferred term, n (%) n = 93 n = 78 n = 66 n = 62 n = 50 n = 36
Akathisia 11 (11.8) 1 (1.3) 1 (1.5) 0 0 0
Insomnia 11 (11.8) 1 (1.3) 0 0 1 (2.0) 0
Weight increased 4 (4.3) 0 4 (6.1) 3 (4.8) 0 0
Headache 4 (4.3) 3 (3.8) 0 1 (1.6) 0 0
Nasopharyngitis 0 4 (5.1) 1 (1.5) 3 (4.8) 0 0
Agitation 7 (7.5) 0 0 0 0 0
Anxiety 5 (5.4) 1 (1.3) 0 1 (1.6) 0 0
Dizziness 4 (4.3) 2 (2.6) 1 (1.5) 0 0 0
Psychotic disorder 1 (1.1) 2 (2.6) 0 2 (3.2) 2 (4.0) 0
Schizophrenia 3 (3.2) 1 (1.3) 2 (3.0) 0 1 (2.0) 0
Tremor 5 (5.4) 1 (1.3) 1 (1.5) 0 0 0
Extrapyramidal disorder 5 (5.4) 0 1 (1.5) 0 0 0
Constipation 3 (3.2) 1 (1.3) 0 0 1 (2.0) 0
Diarrhea 4 (4.3) 0 0 1 (1.6) 0 0
Dyspepsia 4 (4.3) 0 0 1 (1.6) 0 0
Sedation 4 (4.3) 0 0 0 1 (2.0) 0
Somnolence 4 (4.3) 1 (1.3) 0 0 0 0
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Mean change in body weight was +1.9 kg (1.5 kg in pa-
tients who received cariprazine in the lead-in study [n = 53]
and 2.4 kg in both lead-in placebo patients [n = 15] and lead-in
risperidone patients [n = 25]). Mean change from lead-in base-
line to week 0 of the extension study (prior to open-label
cariprazine treatment in this study) in the placebo, cariprazine,
or risperidone lead-in groups was 0.9, 0.5, and 1.8 kg, respec-
tively. Potentially clinically significant (PCS) weight gain
(≥7 % increase from lead-in baseline) was experienced by
31 (33.3 %) patients, 5 of whom experienced weight increase
of ≥15 %. Most (61 %) of the 31 patients who experienced
≥7 % weight increase were in the normal or underweight
baseline BMI categories at baseline; 26 and 13 % were over-
weight and obese, respectively. PCS weight decrease (≤7 %
decrease from lead-in baseline) was experienced by seven
(7.5 %) patients.
Suicidality
Mean STS total score was unchanged during open-label treat-
ment. As previously described, one male patient taking
cariprazine 4.5 mg/day completed suicide. The patient had
no history of suicidal ideation or behavior recorded on his
STS scale, and the event was not considered to be treatment-
related.
Extrapyramidal symptoms
Treatment-emergent parkinsonism (SAS total score ≤3 at
baseline and >3 postbaseline) was reported in eight (8.6 %)
patients, which is consistent with rates that were reported in
the cariprazine and risperidone groups during the lead-in study
(approximately 8–10 %). Treatment-emergent akathisia
(BARS total score ≤2 at baseline and >2 postbaseline) was
reported in 16 (17.2 %) patients, which is slightly higher than
rates reported in the cariprazine and risperidone groups during
the lead-in study (approximately 10–15 %). The most com-
mon EPS-related TEAEs during open-label treatment were
akathisia (13 patients [14.0 %]), tremor (7 [7.5 %]), and ex-
trapyramidal disorder (6 [6.5 %]); all were considered mild or
moderate and no patient discontinued because of EPS-related
TEAEs. Mean (SD) change from baseline to end of study in
AIMS, BARS, and SAS scores was +0.2 (1.6), 0.0 (1.0), and
−0.4 (1.7), respectively.
Ophthalmological examinations
There were no clinically significant changes in ophthalmolog-
ic parameters, including intraocular pressure, color discrimi-
nation, visual acuity, or lens opacity. Ocular TEAEs were
reported in three (3.2 %) patients (blepharitis and corneal
opacity [one patient], vision blurred [one patient], and cataract
[one patient]). None of the ocular events were serious or led to
premature discontinuation. The one reported adverse event of
cataract involved a patient who completed 48 weeks of open-
label treatment. The patient’s dose was adjusted early in the
study and was eventually maintained on a dose of 3 mg/day
for 285 days. No baseline ophthalmology assessments were
conducted as this study was amended to include ophthalmol-
ogy assessments after the patient had taken the first dose of
study drug in both the lead-in and extension studies. There
were no abnormal findings during the first ophthalmology
examination on study day 211 or the examination on study
day 227. On day 337 (the last visit of the open-label treatment
period), an AE of cataract was reported when posterior sub-
capsular opacification increased from 0.1 to 2.7 units in the
left eye. On day 374 and on day 395, left eye values for
posterior subcapsular opacification decreased to 0.8 and
0.4 units, respectively. The cataract was considered resolved
on day 374, 38 days after the patient’s last dose of open-label
treatment. As the complete regression of a cataract is an un-
usual phenomenon, expert advice from an independent oph-
thalmologist was sought. The expert ophthalmologist deter-
mined that the reported AE was likely due to variability on
the part of the examiner and did not represent an actual path-
ological event because (1) posterior subcapsular cataract of a
magnitude to receive a 2.7 LOCS III grading rarely, if ever,
occurs with any drug given for such a brief duration; (2) a 2.7
LOCS III grading level represents the observable expression
Table 5 Changes in vital signs, cardiovascular, and physical findings
(safety population)
Assessment Na Cariprazine
Blood pressure and pulse, mean change (SD)
Systolic blood pressure, mmHg 93 0.6 (10.1)
Diastolic blood pressure, mmHg 93 0.2 (8.1)
Pulse, bpm 93 −1.3 (11.1)
Electrocardiogram, mean change (SD)
Ventricular heart rate, bpm 91 −2.5 (15.6)
QRS interval, ms 91 1.2 (7.0)
PR interval, ms 91 0.8 (15.1)
QT interval, ms 91 3.2 (31.5)
QTcB, ms 91 −2.3 (21.2)
QTcF, ms 91 −0.2 (17.9)
Body weight, mean change (SD)
Body weight, kg 93 1.87 (4.69)
Waist circumference, cm 79 3.09 (9.63)
PCS changes (≥7 %) in body weight, %
≥7 % increase from baseline 93 33.3
≥7 % decrease from baseline 93 7.5
QTcBQT interval corrected for heart rate using the Bazett formula,QTcF
QT interval corrected for heart rate using the Fridericia formula
a Patients in the safety population who had ≥1 postbaseline measurement
for the given parameter
Psychopharmacology (2017) 234:199–209 205
of true tissue pathology and, as such, it is not evanescent and
would not disappear over a period of weeks; and (3) drug-
induced toxic cataract is a bilateral disorder.
Efficacy
The primary objective of this study was to evaluate the long-
term safety and tolerability of open-label cariprazine in adult
patients with schizophrenia; therefore, no inferential statistical
analyses were performed for the efficacy parameters.
Decreases from the lead-in and extension baselines were ob-
served in PANSS total score, PANSS Positive and Negative
Subscale scores, and CGI-S scores at the end of open-label
cariprazine treatment (Table 6 and Supplemental Table 1).
Discussion
This single-arm, open-label extension study supports the long-
term safety and tolerability of cariprazine in patients with
acute exacerbation of schizophrenia. Safety and tolerability
outcomes from 48 weeks of open-label cariprazine treatment
were consistent with those observed in the double-blind lead-
in study (Durgam et al. 2014), with no new or unexpected
findings. Although this study was designed to assess safety
and tolerability, efficacy measures were collected, and it is
noteworthy that there was no signal of worsening efficacy
with continued cariprazine treatment for up to 1 year. These
results are important given the chronic nature of schizophrenia
that often necessitates continuous long-term treatment in order
to manage symptoms and prevent relapse (Higashi et al.
2013).
The TEAE profile during long-term treatment was similar
to that of the lead-in study. The most common TEAEs (≥10 %
at any dose) during the 6-week lead-in study were insomnia,
extrapyramidal disorder, akathisia, and constipation (Durgam
et al. 2014). Similarly, the most common (≥10 %) TEAEs
during the 48-week extension study were akathisia, insomnia,
and weight increased. While SAEs occurred at a higher inci-
dence in the extension study compared with the short-term
lead-in study, the only SAEs that occurred in >1 patient during
the extension study were related to the worsening of schizo-
phrenia. Approximately 11 % of patients in the long-term
study discontinued due to AEs, compared to 6–10 % of
cariprazine patients, and 15 and 9 % of placebo and risperi-
done patients, respectively, during the lead-in study (Durgam
et al. 2014).
Glucose dysregulation, lipid changes, and weight gain are
commonly reported with atypical antipsychotic treatment and
likely contribute to increased cardiovascular risk factors (Goff
et al. 2005). At the end of the 6-week lead-in study, there were
mean decreases in total cholesterol, LDL cholesterol, and tri-
glyceride levels in the cariprazine group andmean increases in
the risperidone group. At the end of the 48-week cariprazine
treatment period, mean total and LDL cholesterol remained
decreased from lead-in baseline and HDL levels were in-
creased slightly from lead-in baseline. Mean triglyceride and
glucose levels increased only slightly from lead-in baseline
levels, indicating very little change over the course of the 1-
year treatment period. Additionally, the percentage of patients
that shifted from normal/borderline lipid or glucose values at
baseline to high values at the end of open-label treatment was
low. There were no clinically significant metabolic changes
that were classified as an SAE or led to study discontinuation.
These results suggest that long-term cariprazine treatment of
up to 1-year duration was not associated with significant dys-
lipidemia or glucose dysregulation.
Increases in weight from lead-in baseline to end of exten-
sion study were greater in patients who received placebo
(2.4 kg) or risperidone (2.4 kg) during the lead-in study com-
pared with patients who received cariprazine (1.5 kg).
However, mean changes from lead-in baseline to week 0 of
the extension study were 0.5 kg in cariprazine lead-in patients
and 0.9 and 1.8 kg in placebo and risperidone lead-in patients,
respectively, suggesting that a substantial portion of the
weight increase in the risperidone lead-in group may have
occurred prior to initiation of open-label cariprazine treatment.
Increases of at least 7 % of baseline body weight occurred
in approximately one third of cariprazine-treated patients dur-
ing the open-label treatment period; conversely, approximate-
ly 8 % of patients experienced clinically significant decreases
in body weight. There were no SAEs or discontinuations as-
sociated with body weight changes. Clinically significant in-
creases in weight were most frequent in patients who were
classified as underweight or normal BMI at baseline (19 of
the 31 incidences) and least frequent in patients classified as
obese at baseline (4 incidences).
The incidence of akathisia as a TEAE in this study was
similar to that observed in previous short-term studies of
cariprazine (Durgam et al. 2015; Kane et al. 2015) and com-
parable with rates associated with other second-generation
agents (Kane et al. 2009). All incidences of akathisia in the
study were mild or moderate in intensity, and mean BARS
scores were unchanged at the end of treatment. No EPS-
related TEAE resulted in premature discontinuation from the
study.
Long-term cariprazine treatment was not associated with
prolactin elevation, high levels of sedation or somnolence, or
clinically significant changes in cardiovascular parameters.
The distinct receptor binding profile of cariprazine may con-
tribute to the differential safety and tolerability profile relative
to other antipsychotics. Cariprazine has low affinity for adren-
ergic and cholinergic receptors and has low potential for
inhibiting hERG channel activity, features which may reduce
the risk of cardiovascular adverse effects, including orthostatic
hypotension and QT prolongation (Leung et al. 2012).
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Similarly, the low affinity of cariprazine for histaminergic re-
ceptors may explain the lack of sedative effects (Miller 2004)
at therapeutic doses. Unlike some antipsychotics with high
affinity for dopamine D2 receptors, cariprazine did not result
in increased prolactin elevation; this finding suggests that par-
tial agonist activity of cariprazine at dopamine D2 receptors
does not impair tuberoinfundibular pathway function (Kapur
and Seeman 2001).
Ophthalmology testing was initiated in the cariprazine clinical
development program in response to ocular findings observed in
the nonclinical program (i.e., cataract formation in dogs and mel-
anin binding in the mass balance study in pigmented rats). No
evidence of retinal toxicity or lenticular changes of clinical signif-
icance has been found in short- or long-term cariprazine clinical
studies and, consistent with these findings, no clinically signifi-
cant ophthalmologic changes were observed in this long-term
cariprazine study.
This study was limited by its open-label design and lack of
placebo or active comparator arm. In addition, as participants in
this study were required to complete a previous 6-week placebo-
and active-controlled study, the population in this study may re-
flect patients who responded to and tolerated initial treatment and
may not be generalizable to all patients. Further, the extension
study was initiated 9 months after the initiation of the lead-in
study; therefore, patients who were enrolled early into the lead-
in study may not have been available to enroll in the extension
phase. While all patients underwent a 1-week washout period,
differences in lead-in study treatments (placebo, cariprazine, or
risperidone) may confound interpretation of some results as
changes in safetyparameterswere assessed relative to thebaseline
of the lead-in study.Although efficacymeasureswere collected, it
is difficult to interpret efficacy in a long-term, single-arm, open-
label trial due to the lack of a control group and the influence of
study dropouts on mean changes in rating scale values. Finally,
this study assessed the long-term safety and tolerability of
cariprazine at doses of 1.5 to 4.5 mg/day; investigation of the
long-term safety of the highest recommended dose of cariprazine
(6 mg/day) is needed.
In conclusion, this study shows that open-label treatment
with cariprazine at flexible doses ranging from 1.5 to 4.5 mg/
Table 6 Change in Efficacy
Scores From Baseline to Week 48
(OC) (ITT Population)
Cariprazine
Efficacy measures N Mean (SEM) score Mean (SEM) change from:
Lead-in baselinea Extension baselineb
PANSS Total Score
Lead-in baseline 92 97.3 (0.8) — —
Extension baseline 92 65.6 (1.4) — —
At Week 6 77 59.2 (1.3) -37.9 (1.2) -6.5 (1.0)
At Week 12 69 57.2 (1.4) -39.9 (1.3) -7.5 (1.2)
At Week 24 58 55.3 (1.4) -42.1 (1.4) -9.2 (1.0)
At Week 48 45 52.4 (2.0) -44.8 (1.8) -11.6 (1.4)
End of open-label
treatmentc
92 58.9 (1.6) -38.5 (1.5) -6.8 (1.3)
CGI-S Score
Lead-in baseline 92 4.7 (0.1) — —
Extension baseline 92 3.0 (0.1) — —
At Week 6 77 2.7 (0.1) -2.1 (0.1) -0.3 (0.1)
At Week 12 69 2.7 (0.1) -2.1 (0.1) -0.3 (0.1)
At Week 24 58 2.6 (0.1) -2.2 (0.1) -0.4 (0.1)
At Week 48 45 2.4 (0.1) -2.3 (0.1) -0.6 (0.1)
End of open-label
treatmentc
92 2.7 (0.1) -2.0 (0.1) -0.3 (0.1)
a Lead-in baseline values were assessed 1 day prior to the first dose of double-blind treatment in the lead-in study.
b Extension baseline values were assessed at visit 2 (study week 0 following the screening period) of the open-
label study.
c Last observation carried forward (LOCF) approach.
CGI-S indicates Clinical Global Impressions-Severity; PANSS, Positive and Negative Syndrome Scale; SEM,
standard error of the mean.
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day was generally safe and well tolerated for up to 1 year
without any apparent loss of efficacy. The results of this
long-term extension study are similar to those observed in
the short-term double-blind lead-in study and indicate that
there are no new safety concerns associated with open-label
long-term treatment. These findings support the long-term use
of cariprazine in patients with schizophrenia.
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